Knowhow offering
|
| Title | Continuous integrated platform for the manufacturing of Ranibizumab Biosimilar |
| Knowhow is available for | Continuous integrated platform for the manufacturing of Ranibizumab Biosimilar |
| Summary | |
| Advantages | 1. Novel refolding process that results in a refolding yield of 30-35% vs the industry standard of 15%.
2. Novel continuous processing platform that results in reduction in cost of manufacturing by 80% for clinical and 75% for commercial production.
Other Advantages:
1. Industry not yet crowded: 1st ever Biosimilar of Ranibizumab- ‘Razumab’ launched by Intas Pharma in 2015. Few players globally.
2. A 2021 survey of Indian vitreoretinal specialists showed progressive trend favouring ranibizumab-biosimilar over bevacizumab-biosimilar.
|
|
Knowhow is listed under following categories
|
Knowhow from
| |
| Scientific/ engineering subject areas |
Life sciences/ biosciences & engineering |
| Investor interest categories |
Biotechnology/ Biomedical/ Health Technologies |
| Industries |
Pharmaceuticals, Bulk Drugs, Formulations |
| Customer categories and nature of business |
Businesses and other industries (B2B) |
| Technology readiness levels
|
TRL B: Proof-of-concept demonstrated in lab scale |
|
Related documents:
|
|
(Local uploaded copy)
|
|
Database reference
|
| Database record number |
20220105022904 |
| Date of upload |
5 / Jan / 2022 |
| Date of update |
|
| URL to site when communicating about this knowhow |
http://techex.in/khdb/viewrecord.php?recordno=20220105022904 |
| Request for this technology |
Click here for Request Form |
